A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa
Recruiting · Phase 1, Phase 2 · NCT06891885
Conditions: Retinitis Pigmentosa
At a glance
- Research payments reported, 2025
- $34,222
- U.S. investigators named
- 2
- Sites paid
- 3
- Planned or actual enrollment
- 12
About the trial
- Sponsor
- Sumitomo Pharma America, Inc.
- Tested
- DSP-3077 Retinal Sheet Cohort 1 (drug), DSP-3077 Retinal Sheet Cohort 2 (drug), DSP-3077 Retinal Sheet Cohort 3 (drug)
- Dates
- Started 2026-04-16; completion 2032-10-31
- Results posted
- Not yet
The Goal of this study is to evaluate the safety, tolerability, and clinical responses following single dose of DSP-3077. Study enrolls both male and female patients in 3 cohorts with each cohort defined by visual acuity (VA) criteria and dose level of DSP-3077. Each cohort will include 4 participants.
From ClinicalTrials.gov, last updated 2026-04-17. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sumitomo Pharma America, Inc. reported $34,222 in research payments for this study in 2025 (22 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Demetrios Vavvas, M.D.,PHD Ophthalmology · Boston, MA
- Sandra R. Montezuma, M.D. Ophthalmology · Plymouth, MN
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Massachusetts Eye and Ear Infirmary -, MA $32,842
- Massachussets Eye and Ear $690
- University of Minnesota Medical School Ophthalmology Clinic $690
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.